Soft Tissue Sarcoma

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

The probability of overall survival after 1, 5, and 10 years was predicted by a nomogram model, which found that worse Surveillance, Epidemiology, and End Results (SEER) stage was associated with worse outcomes.

These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations.

Rhabdomyosarcoma, a common form of soft tissue sarcoma in pediatric patients with outcomes that have improved through research, is rare among older patients, who also have significantly poorer outcomes.

In this analysis, outcomes were investigated among 41 pediatric and young adult patients who had soft-tissue sarcoma and were aged 0 months to 22 years.

Afami-cel, sold as Tecelra by Adaptimmune, is the first gene therapy to be approved for the rare form of cancer and the first FDA-approved T-cell receptor gene therapy.

A study demonstrates the value of incorporating protein signatures in creating more advanced prediction tools for patient outcomes.

The Alliance AO91902 trial investigated whether adding immunotherapy to chemotherapy would improve outcomes for patients with advanced angiosarcoma.

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma.

To conclude our interview with him, Ravin Ratan, MD, MEd, of MD Anderson, explains the importance of caring for all patients and why he tries to own the process of patients feeling confident that they received the attention they deserve.

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years.

The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.

Patients in this analysis were treated between 2007 and 2020 and could have received radiotherapy either before or after surgery for soft tissue sarcoma (STS).

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas.

Investigators from Germany conducted a systematic review of different MRI features in soft tissue sarcoma (STS) that are used to infer tumor histological grade.

Ravin Ratan, MD, MEd, MD Anderson, delves into how treatment paradigms and considerations differ between adult patients and pediatric patients who have soft tissue sarcomas.

Investigators explored the utility of unplanned resections, also called reresection, among patients who have soft tissue sarcomas.

Ravin Ratan, MD, MEd, of The University of Texas MD Anderson Cancer Center, explains the origins of soft tissue sarcomas within the body—which account for 1% of cancers in adult patients—how they are classified, and how they differ from organ-based cancers.

Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells.

The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.

Investigators also examined which type of immunosuppression was associated with a higher likelihood of Kaposi sarcoma.

New guidance on managing desmoid fibromatosis recommends a more conservative approach, encompassing the patient perspective, active surveillance, tumor location, and risk-benefit assessment.

In this retrospective analysis, outcomes data were evaluated on patients receiving care related to extrapleural pneumonectomy for soft tissue sarcoma or bone sarcoma.

Results presented at the National Community Oncology Dispensing Association International Spring Forum describe meaningful improvements in functioning among patients who received the oral gamma secretase inhibitor to treat progressing desmoid tumors.